Xencor (NASDAQ: XNCR) — Perfil da empresa, notícias e dados financeiros
Xencor develops engineered monoclonal antibodies for cancer and autoimmune diseases, leveraging its technology platform for innovative treatments.
Xencor
Xencor (NASDAQ:XNCR) focuses on developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma, and allergic diseases. The company's technology platform is designed to improve the function and clinical utility of antibody therapeutics. Xencor’s pipeline includes novel antibody candidates currently in clinical development, aimed at providing new treatment options for patients in need. With a commitment to innovation, Xencor's objective is to leverage its XmAb® technology platform to create and develop advanced therapeutic antibodies that can potentially transform the way diseases are treated.
Resumo
Operações
Produtos e/ou serviços de Xencor
- XmAb antibody engineering platform, a suite of technologies for improving antibody drug properties.
- Tidutamab, an investigational bispecific antibody targeting CD3 and solid tumor antigen for cancer therapy.
- Plamotamab, a CD20 x CD3 bispecific antibody designed for the treatment of B-cell malignancies.
- Vibecotamab, a bispecific antibody targeting CD123 and CD3 for acute myeloid leukemia.
- Obexelimab, designed to target B-cell signaling for autoimmune diseases.
- XmAb717, an innovative bispecific antibody for the treatment of various cancers.
equipe executiva do Xencor
- Bassil I. DahiyatCo-Founder, CEO, President & Director
- Bart Jan CornelissenSenior VP & CFO
- John R. DesjarlaisExecutive VP of Research & Chief Scientific Officer
- Celia E. EckertSenior VP, General Counsel & Corporate Secretary
- Charles LilesAssociate Director and Head of Corporate Communications & Investor Relations
- Jennifer SandozSenior VIce President of Human Resources
- Kirk RosemarkSenior Vice President of Regulatory Affairs & Quality Assurance
- Eric P. KowackSenior Vice President of Program Leadership & Alliance Management
- Dane Vincent LeoneExecutive VP & Chief Strategy Officer
- Mark OstermanSenior Vice President of Clinical Development (Autoimmune)
Principais indicadores financeiros
Resultados divulgados pela Xencor, em USD.
- Cap. de mercado
- 2,2 bi
- Receita (TTM)
- 105 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.2
- Dividend yield
- —
- Margem de lucro
- -155.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 125,6 mi | -177,5 mi | -91,9 mi | |
| 110,5 mi | -178,4 mi | -232,6 mi | |
| 168,3 mi | -138,6 mi | -126,1 mi | |
| 164,6 mi | -82,5 mi | -55,2 mi |